p53 dependence of senescence markers p21v1 and p21v2 in aging and acute injury

Materials and methods

Ethics approval statement

The animal use and experiments including hemorrhagic shock injury (HI) described in the study were approved by the Institutional Animal Care and Use Committee (IACUC) at Augusta University and were performed in accordance with the relevant guidelines and regulations.

Animals

The young (3 months old) and old (22–24 months old) C57BL/6 male mice used were either bred in-house or purchased from the National Institute on Aging. All the mice were housed in the vivarium at the Augusta University with a 12 h light/ dark cycle.

Hemorrhagic shock injury procedure

The animals were subjected to sham or HI procedure as described earlier33,34. Briefly, the animals were anesthetized with isoflurane (Henry Schein, Dublin, OH, USA). Both the femoral arteries were cannulated for bleeding, blood pressure monitoring, or fluid resuscitation. Sham animals did not undergo hemorrhage or fluid resuscitation. HI was induced by bleeding rapidly to a MAP of 35 ± 5 mmHg in 45 min by removing ~60% of the total blood volume. The animals were then maintained in a state of shock by maintaining the low MAP for another 45 min, after which fluid resuscitation was carried out with Ringer lactate (RL; twice the volume of shed blood in 1 h). The animals were euthanized at the end of 2 h post-fluid resuscitation, the heart was perfused with ice-cold PBS, and the tissues were collected.

RNA extraction and PCR

RNA was extracted from young, aged and HI tissues using Trizol-reagent (Invitrogen, CA, USA). The RNA quality was ascertained by A260/280 as well as by resolving on 2% agarose gel to assess the 28S and 18S bands. cDNA synthesis was carried out using ImProm-II reverse transcriptase (Promega, WI, USA). The transcripts were analyzed using Bio-rad iTaq Universal SYBR Green Master mix (Bio-rad, CA, USA) in an Agilent real-time PCR machine (Agilent Technologies, CA, USA). The PCR results were normalized to the geometric mean of β-actin, β-glucuronidase and ribosomal protein large P0 (Rplp0)35,36,37. Primer sequences are listed in Supplementary Table 1. 2ΔCt values were used for statistical analyses, and the graphs are represented in log2 scale.

Cell culture and induction of senescence

p53/ and wild-type littermate MEF (WT-MEF) cells were treated with 250 nM–1μM concentrations of doxorubicin for 48 h and harvested for molecular studies. Additionally, an H2O2-induced stress model was used by treating p53/ and wild-type littermate MEF (WT-MEF) cells with 250 μM concentration of H2O2 for 24 h. To examine the expression of senescence markers in replicative senescence, MEF cells from passage three (P3, denoted as early passage) were serially passaged after 80% confluence until passage 13 (P13, denoted as late passage). Cells from early as well as late passage were then used to check the expression of senescence markers p16, p21 and p53.

Indirect immunofluorescence and confocal microscopy

Protein expression of p16 and p21 was assessed by indirect immunofluorescence. Briefly, the cryo-sections were blocked using 2% BSA for 1 h and a cocktail of p21 (1:150, Cat. No sc-6246, Santa Cruz Biotechnology, CA, USA) and p16 (1:100, Cat. No. PA5-20379, Invitrogen, CA, USA) unconjugated primary antibodies were used. The slides were then washed with PBS with and without 0.075% Brij-35 detergent (Thermo Fisher Scientific) and incubated with a cocktail of secondary anti-mouse 488 for p21 (1:1500, Abcam, MA, USA), anti-rabbit 594 for P16 (1:1500, Invitrogen) for 2 h. The slides were again washed and incubated with DAPI (1 µg/ml, Sigma, MO, USA) and mounted with Vectastain mountant (Vector Labs, CA, USA). The images were captured on Leica Stellaris Confocal Microscope (Leica, Hamburg, Germany). The hepatocytes were stained using ASGPR primary antibody tagged with Alexa fluor 594 (1:200, Cat. No. PA5-32030, Invitrogen, CA, USA).

Western blot

Immunoblotting was performed to assess the difference in p21 protein expression among young, aged and HI tissues. Briefly, the tissue samples were first homogenized in the RIPA buffer added with protease and phosphatase inhibitor (Thermo Fisher Scientific, Waltham, MA USA), sonicated and clarified by centrifugation. The protein concentrations were determined by the DC (detergent compatible) protein assay (Bio-Rad Laboratories, Hercules, CA). Then, 40 µg protein was loaded onto a 12% SDS–PAGE, transferred onto polyvinylidene difluoride (PVDF) membrane and probed with p21 (1:200, Cat. No sc-6246, Santa Cruz Biotechnology, CA, USA) and actin (1:1000, Cat. No. ab 179467, Abcam) primary antibody and anti-mouse secondary antibody conjugated with horseradish peroxidase (1:10,000, Cat. No. 7076P2, Cell Signaling, Danvers, MA). The immune complexes were detected by chemiluminescence substrate (Thermo Fisher Scientific, Waltham, MA USA).

Statistical analysis

Experiment appropriate statistical methods were used to analyze the results. The 2ΔCt values for amplified senescence markers in tissues and doxorubicin-treated MEF cells were assessed using the Kruskal–Wallis test. The results of the H2O2-induced stress model were analyzed using a 2-way ANOVA (Uncorrected Fisher’s LSD), while p53 expression for H2O2-induced stress was analyzed using Wilcoxon’s and that of replicative senescence were analyzed by Mann–Whitney test. A p-value of <0.05 was considered as significant. The mRNA expression was assessed in seven mice/group with at least two technical replicates. The in vitro experiments were carried out in triplicates. The statistical analysis was performed using Graph Pad Prism software.

Related Articles

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations

Senescence is a crucial hallmark of ageing and a significant contributor to the pathology of age-related disorders. As committee members of the young International Cell Senescence Association (yICSA), we aim to synthesise recent advancements in the identification, characterisation, and therapeutic targeting of senescence for clinical translation. We explore novel molecular techniques that have enhanced our understanding of senescent cell heterogeneity and their roles in tissue regeneration and pathology. Additionally, we delve into in vivo models of senescence, both non-mammalian and mammalian, to highlight tools available for advancing the contextual understanding of in vivo senescence. Furthermore, we discuss innovative diagnostic tools and senotherapeutic approaches, emphasising their potential for clinical application. Future directions of senescence research are explored, underscoring the need for precise, context-specific senescence classification and the integration of advanced technologies such as machine learning, long-read sequencing, and multifunctional senoprobes and senolytics. The dual role of senescence in promoting tissue homoeostasis and contributing to chronic diseases highlights the complexity of targeting these cells for improved clinical outcomes.

Inhibition of sympathetic tone via hypothalamic descending pathway propagates glucocorticoid-induced endothelial impairment and osteonecrosis of the femoral head

Osteonecrosis of the femoral head (ONFH) is a common complication of glucocorticoid (GC) therapy. Recent advances demonstrate that sympathetic nerves regulate bone homeostasis, and GCs lower the sympathetic tone. Here, we show that the dramatically decreased sympathetic tone is closely associated with the pathogenesis of GC-induced ONFH. GCs activate the glucocorticoid receptor (GR) but hinder the activation of the mineralocorticoid receptor (MR) on neurons in the hypothalamic paraventricular nucleus (PVN). This disrupts the balance of corticosteroid receptors (GR/MR) and subsequently reduces the sympathetic outflow in the PVN. Vascular endothelial cells rapidly react to inhibition of sympathetic tone by provoking endothelial apoptosis in adult male mice treated with methylprednisolone (MPS) daily for 3 days, and we find substantially reduced H-type vessels in the femoral heads of MPS-treated ONFH mice. Importantly, treatment with a GR inhibitor (RU486) in the PVN promotes the activation of MR and rebalances the ratio of GR and MR, thus effectively boosting sympathetic outflow, as shown by an increase in tyrosine hydroxylase expression in both the PVN and the sympathetic postganglionic neurons and an increase in norepinephrine levels in both the serum and bone marrow of the femoral head of MPS-treated mice. Rebalancing the corticosteroid receptors mitigates GC-induced endothelial impairment and ONFH and promotes angiogenesis coupled with osteogenesis in the femoral head, while these effects are abolished by chemical sympathectomy with 6-OHDA or adrenergic receptor-β2 (Adrb2) knockout. Furthermore, activating Adrb2 signaling in vivo is sufficient to rescue the GC-induced ONFH phenotype. Mechanistically, norepinephrine increases the expression of the key glycolytic gene 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) via Adrb2-cyclic AMP response element-binding protein (CREB) signaling. Endothelial-specific overexpression of PFKFB3 attenuates endothelial impairment and prevents severe osteonecrosis in MPS-treated Adrb2 knockout mice. Thus, GC inhibits sympathetic tone via the hypothalamic descending pathway, which, in turn, acts as a mediator of GC-induced ONFH.

Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis

Osteoarthritis (OA) poses a significant challenge in orthopedics. Inflammatory pathways are regarded as central mechanisms in the onset and progression of OA. Growing evidence suggests that senescence acts as a mediator in inflammation-induced OA. Given the lack of effective treatments for OA, there is an urgent need for a clearer understanding of its pathogenesis. In this review, we systematically summarize the cross-talk between cellular senescence and inflammation in OA. We begin by focusing on the mechanisms and hallmarks of cellular senescence, summarizing evidence that supports the relationship between cellular senescence and inflammation. We then discuss the mechanisms of interaction between cellular senescence and inflammation, including senescence-associated secretory phenotypes (SASP) and the effects of pro- and anti-inflammatory interventions on cellular senescence. Additionally, we focus on various types of cellular senescence in OA, including senescence in cartilage, subchondral bone, synovium, infrapatellar fat pad, stem cells, and immune cells, elucidating their mechanisms and impacts on OA. Finally, we highlight the potential of therapies targeting senescent cells in OA as a strategy for promoting cartilage regeneration.

Decoding senescence of aging single cells at the nexus of biomaterials, microfluidics, and spatial omics

Aging has profound effects on the body, most notably an increase in the prevalence of several diseases. An important aging hallmark is the presence of senescent cells that no longer multiply nor die off properly. Another characteristic is an altered immune system that fails to properly self-surveil. In this multi-player aging process, cellular senescence induces a change in the secretory phenotype, known as senescence-associated secretory phenotype (SASP), of many cells with the intention of recruiting immune cells to accelerate the clearance of these damaged senescent cells. However, the SASP phenotype results in inducing secondary senescence of nearby cells, resulting in those cells becoming senescent, and improper immune activation resulting in a state of chronic inflammation, called inflammaging, in many diseases. Senescence in immune cells, termed immunosenescence, results in further dysregulation of the immune system. An interdisciplinary approach is needed to physiologically assess aging changes of the immune system at the cellular and tissue level. Thus, the intersection of biomaterials, microfluidics, and spatial omics has great potential to collectively model aging and immunosenescence. Each of these approaches mimics unique aspects of the body undergoes as a part of aging. This perspective highlights the key aspects of how biomaterials provide non-cellular cues to cell aging, microfluidics recapitulate flow-induced and multi-cellular dynamics, and spatial omics analyses dissect the coordination of several biomarkers of senescence as a function of cell interactions in distinct tissue environments. An overview of how senescence and immune dysregulation play a role in organ aging, cancer, wound healing, Alzheimer’s, and osteoporosis is included. To illuminate the societal impact of aging, an increasing trend in anti-senescence and anti-aging interventions, including pharmacological interventions, medical procedures, and lifestyle changes is discussed, including further context of senescence.

Cell senescence in cardiometabolic diseases

Cellular senescence has been implicated in many age-related pathologies including atherosclerosis, heart failure, age-related cardiac remodeling, diabetic cardiomyopathy and the metabolic syndrome. Here, we will review the characteristics of senescent cells and their endogenous regulators, and summarize the metabolic stressors that induce cell senescence. We will discuss the evidence of cell senescence in the onset and progression of several cardiometabolic diseases and the therapeutic potential of anti-senescence therapies.

Responses

Your email address will not be published. Required fields are marked *